ClinicalTrials.gg
CompletedNCT00961415Updated Feb 22, 2016Results posted

AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer

A Phase 3 interventional study of bevacizumab [Avastin] and cisplatin in Non-Squamous Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Completed at 91 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-22.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
376
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 8 of them phase 3. Cisplatin · Carcinoma, Non-Small-Cell Lung.

Enrollment
28th of 198
376 · median 58
Started
2009
with 21 others
Phase 3
46 of 213
4 open now
Registered
115th of 213
by date
Lead sponsor
5 of 213
Hoffmann-La Roche

Among the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, this one is the 28th largest by enrollment of the 198 interventional ones that give a count, is one of 22 that started in 2009, is one of 46 in phase 3, and was the 115th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This open-label study will assess the efficacy and safety of Avastin with or without pemetrexed as maintenance therapy in patients with advanced, metastatic or recurrent non-small cell lung cancer. In Part 1, patients will receive 4 cycles of treatment with Avastin (7.5mg/kg iv) plus cisplatin (75mg/m2 iv) plus pemetrexed (500mg/m2 iv) on day 1 of each 3-week cycle. In Part 2, patients responding to treatment will be randomized to receive further treatment cycles of Avastin (7.5mg/kg iv every 3 weeks) with or without pemetrexed (500mg/m2 iv every 3 weeks). Anticipated time on study treatment is until disease progression. Target sample size is \<500 individuals.

03

Conditions studied

  • Non-Squamous Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults >/=18 years of age
  • inoperable, locally advanced, or recurrent non-squamous non-small cell lung cancer (NSCLC)
  • at least 1 meeting criteria
  • performance status 0-2
  • adequate hematological, liver and renal function

Exclusion criteria

Exclusion Criteria:

  • prior chemotherapy or treatment with another systemic anti-cancer agent
  • other than NSCLC within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer or DCIS
  • evidence of tumor invading major blood vessels
  • current or recent use of aspirin (>325mg/day) or full-dose anticoagulants or thrombolytic agents for therapeutic purposes
  • history of haemoptysis >/=grade 2
  • cardiovascular disease
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
376 participants (actual)

Study arms

  • Experimental
    Part 1

    Drug: bevacizumab [Avastin] · Drug: cisplatin · Drug: pemetrexed

  • Experimental
    Part 2A

    Drug: bevacizumab [Avastin]

  • Active comparator
    Part 2B

    Drug: bevacizumab [Avastin] · Drug: pemetrexed

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival During Maintenance Treatment Phase

    Progression free survival (PFS) is defined as the time from randomization to the date of documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) , or the date of occurrence of a second primary cancer, or date of death from any cause, whichever comes first. Progression is defined using (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, the appearance of new lesions and increase of at least 5 mm in the sum of diameters of target lesions.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.

    Time frame: Up to 21 months

Secondary outcomes

  1. Overall Survival During Maintenance Treatment Phase

    Overall survival (OS) is assessed from the date of first induction treatment until the date of death. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.

    Time frame: Up to 21 months

  2. Best Overall Response Rate During Maintenance Treatment Phase

    The best overall response rate (BORR) is defined as the percentage of participants having achieved confirmed Complete Response (CR) and Partial Response (PR) as the best overall response. CR was defined as complete disappearance of all target lesions and non-target disease. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. Stable disease (SD) is defined as steady state of disease with neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD).Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.

    Time frame: Up to 21 months

  3. Duration of Response During Maintenance Treatment Phase

    Duration of response is defined as the time in months from the initial start of response PR or better to the earlier of documented PD or death due to any cause. Participants who had neither progressed nor died at the date of clinical cutoff, who withdrew from the study, were lost to follow-up, or were without documented disease progression were censored at the date of the last available tumor assessment. The analysis was based on all participants with measurable disease at baseline who achieved response.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.

    Time frame: Up to 21 months

  4. Duration of Disease Control During Maintenance Treatment Phase

    Duration of disease control is defined as the time in months from randomization to the earlier of documented PD or death due to any cause. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.

    Time frame: Up to 21 months

  5. Incidence of Adverse Events and Serious Adverse Event

    An adverse events (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect, or precaution.

    Time frame: Up to 21 months

  6. Number of Participants With Marked Laboratory Abnormalities

    Marked laboratory abnormalities were defined as those values that were outside the reference range and showed a clinically relevant change from Baseline. The reference range for Platelets was 100-550 (10\^9/L), for White blood cells (WBC) was 3.0-18.0 (10\^9/L), for Lymphocytes was 0.70-7.60 (10\^9/L), and Neutrophil 1.50-9.25 (10\^9/L ).

    Time frame: Up to 21 months

  7. Quality of Life

    European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Cancer 30 (EORTC QLQ-C30): included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Lung Cancer 13 \[EORTC QLQ-LC13\]consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. Scale score range: 0 to 100. Higher symptom score = greater degree of symptom severity. QOL was assessed using Pre-Induction Baseline (Pre-ind BL), Maintenance (MTC), End of study (EOS) cycles.

    Time frame: Up to 21 months

07

Results

Posted Feb 22, 2016

Participant flow

A total of 414 participants were screened out of which 38 participants were excluded for not meeting the eligibility criteria, declining to participate, or for other reasons. A total of 376 participants were recruited over an 18-month period across 81 centers in 11 countries from 17 August 2009 to 3 May 2011.

Induction Treatment Phase
Participant flow — Induction Treatment Phase
MilestoneInduction Treatment PhaseBevacizumab Maintenance Treatment (Trt) Arm ABevacizumab +Pemetrexed Maintenance Trt Arm B
Started37600
Completed25300
Not completed12300
Withdrew: Withdrawal by subject1100
Withdrew: Death7700
Withdrew: Protocol violation100
Withdrew: Physician decision200
Withdrew: Didn't meet maintenance phase criteria2700
Withdrew: Other reason500
Maintenance Treatment Phase
Participant flow — Maintenance Treatment Phase
MilestoneInduction Treatment PhaseBevacizumab Maintenance Treatment (Trt) Arm ABevacizumab +Pemetrexed Maintenance Trt Arm B
Started0125128
Completed07783
Not completed04845
Withdrew: Death04234
Withdrew: Investigators decision020
Withdrew: Withdrawal by subject038
Withdrew: Other reason013

Outcome measures

PrimaryProgression Free Survival During Maintenance Treatment Phase

Progression free survival (PFS) is defined as the time from randomization to the date of documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) , or the date of occurrence of a second primary cancer, or date of death from any cause, whichever comes first. Progression is defined using (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, the appearance of new lesions and increase of at least 5 mm in the sum of diameters of target lesions.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.

Time frame:
Up to 21 months
Reported as:
Median · Months
Progression Free Survival During Maintenance Treatment Phase
MonthsBevacizumab Maintenance Trt Arm ABevacizumab +Pemetrexed Maintenance Trt Arm B
Progression Free Survival During Maintenance Treatment Phase6.6 (6.0 to 7.8)10.2 (9.1 to 11.7)
Statistical analysis
  • Bevacizumab Maintenance Trt Arm A vs Bevacizumab +Pemetrexed Maintenance Trt Arm B · Log Rank · p = <0.001 · Hazard ratio (hr): 0.50 · 95% CI 0.37 to 0.69
SecondaryOverall Survival During Maintenance Treatment Phase

Overall survival (OS) is assessed from the date of first induction treatment until the date of death. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.

Time frame:
Up to 21 months
Reported as:
Median · Months
Overall Survival During Maintenance Treatment Phase
MonthsBevacizumab Maintenance Trt Arm ABevacizumab +Pemetrexed Maintenance Trt Arm B
Overall Survival During Maintenance Treatment Phase15.7 (14.3 to NA)NA (NA to NA)
Statistical analysis
  • Bevacizumab Maintenance Trt Arm A vs Bevacizumab +Pemetrexed Maintenance Trt Arm B · Log Rank · p = 0.230 · Hazard ratio (hr): 0.75 · 95% CI 0.47 to 1.20
SecondaryBest Overall Response Rate During Maintenance Treatment Phase

The best overall response rate (BORR) is defined as the percentage of participants having achieved confirmed Complete Response (CR) and Partial Response (PR) as the best overall response. CR was defined as complete disappearance of all target lesions and non-target disease. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. Stable disease (SD) is defined as steady state of disease with neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD).Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.

Time frame:
Up to 21 months
Reported as:
Number · percentage of participants
Best Overall Response Rate During Maintenance Treatment Phase
percentage of participantsBevacizumab Maintenance Trt Arm ABevacizumab +Pemetrexed Maintenance Trt Arm B
Partial response (PR)50 (40.9 to 59.1)55.5 (46.4 to 64.3)
Stable disease (SD)50 (40.9 to 59.1)44.5 (35.7 to 53.6)
SecondaryDuration of Response During Maintenance Treatment Phase

Duration of response is defined as the time in months from the initial start of response PR or better to the earlier of documented PD or death due to any cause. Participants who had neither progressed nor died at the date of clinical cutoff, who withdrew from the study, were lost to follow-up, or were without documented disease progression were censored at the date of the last available tumor assessment. The analysis was based on all participants with measurable disease at baseline who achieved response.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.

Time frame:
Up to 21 months
Reported as:
Median · Months
Duration of Response During Maintenance Treatment Phase
MonthsBevacizumab Maintenance Trt Arm ABevacizumab +Pemetrexed Maintenance Trt Arm B
Duration of Response During Maintenance Treatment Phase5.7 (4.9 to 7.2)9.2 (6.8 to 10.4)
Statistical analysis
  • Bevacizumab Maintenance Trt Arm A vs Bevacizumab +Pemetrexed Maintenance Trt Arm B · Log Rank · p = 0.006 · Hazard ratio (hr): 0.53 · 95% CI 0.34 to 0.84
SecondaryDuration of Disease Control During Maintenance Treatment Phase

Duration of disease control is defined as the time in months from randomization to the earlier of documented PD or death due to any cause. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.

Time frame:
Up to 21 months
Reported as:
Median · Months
Duration of Disease Control During Maintenance Treatment Phase
MonthsBevacizumab Maintenance Trt Arm ABevacizumab +Pemetrexed Maintenance Trt Arm B
Duration of Disease Control During Maintenance Treatment Phase4.9 (3.9 to 5.7)7.8 (6.8 to 9.7)
Statistical analysis
  • Bevacizumab Maintenance Trt Arm A vs Bevacizumab +Pemetrexed Maintenance Trt Arm B · Log Rank · p = <0.001 · Hazard ratio (hr): 0.52 · 95% CI 0.38 to 0.70
SecondaryIncidence of Adverse Events and Serious Adverse Event

An adverse events (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect, or precaution.

Time frame:
Up to 21 months
Reported as:
Number · Participants
Incidence of Adverse Events and Serious Adverse Event
ParticipantsBevacizumab Maintenance Trt Arm ABevacizumab +Pemetrexed Maintenance Trt Arm BNo Maintenance Trt
AE116123119
SAE264270
SecondaryNumber of Participants With Marked Laboratory Abnormalities

Marked laboratory abnormalities were defined as those values that were outside the reference range and showed a clinically relevant change from Baseline. The reference range for Platelets was 100-550 (10\^9/L), for White blood cells (WBC) was 3.0-18.0 (10\^9/L), for Lymphocytes was 0.70-7.60 (10\^9/L), and Neutrophil 1.50-9.25 (10\^9/L ).

Time frame:
Up to 21 months
Reported as:
Number · Participants
Number of Participants With Marked Laboratory Abnormalities
ParticipantsBevacizumab Maintenance Trt Arm ABevacizumab +Pemetrexed Maintenance Trt Arm BNo Maintenance Trt
Alanine amino transferase (ALT)18268
Aspartate amino transferase (AST)18268
Alkaline phosphatase18268
Hemoglobin283025
International normalized ratio (INR)100
Lymphocytes283025
Neutrophils283025
Platelets283025
Serum creatinine18268
WBC283025
Activated partial thromboplastin time (aPTT)100
SecondaryQuality of Life

European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Cancer 30 (EORTC QLQ-C30): included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Lung Cancer 13 \[EORTC QLQ-LC13\]consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. Scale score range: 0 to 100. Higher symptom score = greater degree of symptom severity. QOL was assessed using Pre-Induction Baseline (Pre-ind BL), Maintenance (MTC), End of study (EOS) cycles.

Time frame:
Up to 21 months
Reported as:
Mean · Score on scale
Quality of Life
Score on scaleBevacizumab Maintenance Trt Arm ABevacizumab +Pemetrexed Maintenance Trt Arm B
[Pre-ind BL] Global Health Status Scale n=116,12157.9 ± 23.9059.7 ± 21.74
[Pre-ind BL] Physical Functional Scale (n=118,121)74.8 ± 23.6979.4 ± 18.09
[Pre-ind BL] Role Functional Scale (n=118,121)68.4 ± 32.5071.1 ± 28.28
[Pre-ind BL] Emotional Functional Scale n=117,12171.7 ± 21.9369.8 ± 21.97
[Pre-ind BL] Cognitive Functional Scale n=117,12186.0 ± 21.5588.0 ± 16.70
[Pre-ind BL]] Social Functional Scale (n=116,120)79.3 ± 25.6078.7 ± 26.10
[Pre-ind BL] Fatigue Symptom Scale (n=118,121)33.3 ± 27.1831.5 ± 21.73
[Pre-ind BL] Nausea & Vomiting Scale n=118,1217.2 ± 17.504.3 ± 12.46
[Pre-ind BL] Pain Symptom Scale (n=118,121)36.7 ± 31.9224.7 ± 26.88
[Pre-ind BL] Dyspnea Symptom Scale (n=118,121)29.7 ± 30.7530.6 ± 29.69
[Pre-ind BL] Insomnia Symptom Scale n=118,12133.3 ± 34.5933.9 ± 30.42
[Pre-ind BL] Appetite Loss Symptom Scale n=118,12119.2 ± 30.0118.7 ± 29.15
[Pre-ind BL]] Constipation Symptom Scale n=118,12118.6 ± 30.689.1 ± 20.18
[Pre-ind BL] Diarrhea Symptom Scale (n=117,121)7.1 ± 17.965.2 ± 14.91
[Pre-ind BL]Financial Difficulties Scale n=114,12017.3 ± 30.4817.2 ± 29.62
[MTC Cycle 3]Global Health Status (n=69,87)63.3 ± 20.0258.6 ± 19.71
[MTC Cycle 3]Physical Functional Scale (n=69,87)77.1 ± 20.7276.0 ± 20.37
[MTC Cycle 3]Role Functional Scale (n=69,87)74.2 ± 27.7969.9 ± 28.51
[MTC Cycle 3]Emotional Functional Scale (n=69,87)82.5 ± 19.8678.4 ± 18.48
[MTC Cycle 3]Cognitive Functional Scale (n=69,87)84.3 ± 23.2082.6 ± 19.17
[MTC Cycle 3]Social Functional Scale (n=69,87)82.1 ± 25.6273.0 ± 24.28
[MTC Cycle 3]Fatigue Symptom Scale (n=69,87)32.1 ± 22.8834.5 ± 21.50
[MTC Cycle 3]Nausea and Vomiting Scale (n=69,87)7.2 ± 16.788.8 ± 12.92
[MTC Cycle 3]Pain Symptom Scale (n=69,87)23.9 ± 27.6417.4 ± 21.85
[MTC Cycle 3]Dyspnea Symptom Scale (n=69,87)26.1 ± 27.9329.9 ± 26.91
MTC Cycle 3]Appetite Loss Symptom Scale (n=69,87)13.5 ± 22.3718.4 ± 25.80
[MTC Cycle 3]Insomnia Symptom Scale (n=69,87)19.3 ± 24.5319.5 ± 25.19
[MTC Cycle 3]Constipation Symptom Scale (n=69,87)10.1 ± 19.2211.1 ± 20.12
[MTC Cycle 3]Diarrhea Symptom Scale (n=69,87)3.4 ± 12.975.7 ± 14.56
[MTC Cycle 3]Financial Difficulties Scale (n=68,8618.1 ± 27.8819.4 ± 26.30
[MTC Cycle 5] Global Health Status (n=51,77)63.2 ± 20.3662.9 ± 18.81
[MTC Cycle 5] Physical Functional Scale (n=51,77)78.7 ± 21.2978.4 ± 15.45
[MTC Cycle 5] Role Functional Scale (n=51,77)74.5 ± 31.1568.8 ± 27.08
[MTC Cycle 5] Emotional Functional Scale (n=51,77)78.8 ± 23.7678.7 ± 20.96
[MTC Cycle 5] Cognitive Functional Scale (n=51,77)81.0 ± 26.0484.6 ± 18.09
[MTC Cycle 5] Social Functional Scale (n=51,77)85.3 ± 22.5277.9 ± 22.85
[MTC Cycle 5] Fatigue Symptom Scale (n=51,77)32.2 ± 23.0134.5 ± 22.12
[MTC Cycle 5] Nausea and Vomiting Scale (n=51,77)9.2 ± 18.0510.0 ± 20.10
[MTC Cycle 5] Pain Symptom Scale (n=51,77)23.5 ± 26.2820.1 ± 25.27
[MTC Cycle 5] Dyspnea Symptom Scale (n=51,77)25.5 ± 27.9635.9 ± 30.95
[MTC Cycle 5] Insomnia Symptom Scale( n=51,77)21.6 ± 28.9222.1 ± 27.36
MTC Cycle 5] Appetite Loss Symptom Scale (n=51,77)10.5 ± 19.4319.9 ± 26.63
[MTC Cycle 5] Constipation Symptom Scale (n=51,77)9.2 ± 20.0917.3 ± 29.42
[MTC Cycle 5] Diarrhea Symptom Scale (n=51,77)10.5 ± 20.542.6 ± 8.99
[MTC Cycle 5] Financial Difficulties Scale n=50,7716.0 ± 28.7617.7 ± 23.31
[MTC Cycle 7] Global Health Status Scale (n=38,64)61.2 ± 21.6961.3 ± 19.55
[MTC Cycle 7] Physical Functional Scale (n=38,64)75.6 ± 21.4974.7 ± 19.38
[MTC Cycle 7]Role Functional Scale (n=38,64)76.8 ± 24.9770.8 ± 28.79
[MTC Cycle 7]Emotional Functional Scale (n=38,64)81.6 ± 22.2777.5 ± 18.64
[MTC Cycle 7]Cognitive Functional Scale (n=38,64)77.2 ± 27.5181.0 ± 18.98
[MTC Cycle 7]Social Functional Scale (n=38,64)82.9 ± 24.3572.1 ± 28.65
[MTC Cycle 7]Fatigue Symptom Scale (n=38,64)32.3 ± 22.0733.7 ± 24.72
[MTC Cycle 7]Nausea & Vomiting Scale (n=38,64)8.3 ± 18.889.6 ± 16.48
[MTC Cycle 7]Pain Symptom Scale (n=38,64)21.5 ± 23.8619.8 ± 23.55
[MTC Cycle 7]Dyspnea Symptom Scale (n=38,64)28.1 ± 26.3137 ± 32.59
[MTC Cycle 7]Insomnia Symptom Scale (n=38,64)16.7 ± 26.5728.6 ± 30.21
[MTC Cycle 7]Appetite Loss Scale (n=38,64)12.3 ± 21.1121.4 ± 29.32
[MTC Cycle 7]Constipation Symptom Scale (n=38,64)14 ± 28.6117.2 ± 24.48
[MTC Cycle 7]Diarrhea Symptom Scale (n=38,64)8.8 ± 20.048.9 ± 21.61
[MTC Cycle 7]Financial Difficulties Scale n=38,6414.0 ± 24.0520.3 ± 27.61
[MTC Cycle 9 ]Global Health Status Scale (n=33,50)60.6 ± 18.6761.2 ± 17.71
[MTC Cycle 9 ]Physical Functional Scale (n=33,50)80.8 ± 20.5374.9 ± 19.54
[MTC Cycle 9 ]Role Functional Scale (n=33,50)75.8 ± 24.3369.7 ± 28.51
[MTC Cycle 9 ]Emotional Functional Scale (n=33,50)82.3 ± 18.6175 ± 22.46
[MTC Cycle 9 ]Cognitive Functional Scale (n=33,50)83.3 ± 20.4181.7 ± 19.99
[MTC Cycle 9 ]Social Functional Scale (n=33,50)83.8 ± 24.4771.7 ± 26.78
[MTC Cycle 9 ]Fatigue Symptom Scale (n=33,50)28.3 ± 24.0735.1 ± 25.03
[MTC Cycle 9 ]Nausea & Vomiting Symptom (n=33,50)5.1 ± 12.1412.0 ± 20.77
[MTC Cycle 9 ]Pain Symptom Scale (n=33,50)25.8 ± 30.9318.7 ± 21.47
[MTC Cycle 9 ]Dyspnea Symptom Scale (n=32,50)25.0 ± 25.4035.3 ± 27.28
[MTC Cycle 9 ]Insomnia Symptom Scale (n=33,49)23.2 ± 26.9830.6 ± 33.91
[MTC Cycle 9 ]Appetite Loss Scale (n=33,50)10.1 ± 19.5223.3 ± 29.55
[MTC Cycle 9 ]Constipation Symptom Scale (n=33,50)13.1 ± 24.9216.0 ± 25.41
[MTC Cycle 9 ]Diarrhea Symptom Scale (n=33,50)7.1 ± 207.3 ± 18.18
[MTC Cycle 9]Financial Difficulties Scale n=33,5015.2 ± 23.7022.0 ± 27.45
[MTC Cycle 11 ] Global Health Status Scale n=25,3757.7 ± 18.9359.9 ± 21.41
[MTC Cycle 11 ]Physical Functional Scale (n=25,37)79.2 ± 16.4881.1 ± 17.81
[MTC Cycle 11 ]Role Functional Scale (n=25,37)77.3 ± 18.5673.9 ± 27.37
[MTC Cycle 11 ]Emotional Functional Scale n=25,3778.3 ± 19.0980.0 ± 19.88
[MTC Cycle 11 ]Cognitive Functional Scale n=25,3781.3 ± 26.4984.2 ± 17.10
[MTC Cycle 11 ]Social Functional Scale (n=25,37)84.7 ± 19.2077.9 ± 27.51
[MTC Cycle 11 ]Fatigue Symptom Scale (n=25,37)32.4 ± 22.2031.2 ± 20.92
[MTC Cycle 11 ]Nausea & Vomiting Scale (n=25,37)6.7 ± 15.969.5 ± 18.23
[MTC Cycle 11 ]Pain Symptom Scale (n=25,37)29.3 ± 28.9819.8 ± 27.45
[MTC Cycle 11 ]Dyspnea Symptom Scale (n=25,37)30.7 ± 16.4428.8 ± 27.40
[MTC Cycle 11 ]Insomnia Symptom Scale (n=25,37)20.0 ± 23.5718.9 ± 26.69
[MTC Cycle 11 ]Appetite Loss Scale (n=25,37)9.3 ± 20.4618 ± 26.75
MTC Cycle 11 ]Constipation Symptom Scale( n=25,37)6.7 ± 13.6117.1 ± 24.37
[MTC Cycle 11 ]Diarrhea Symptom Scale ( n=25,37)1.3 ± 6.677.2 ± 15.98
[MTC Cycle 11]Financial Difficulties Scale n=24,3715.3 ± 25.9718.0 ± 26.75
[EOS]Global Health Status Scale (n=123,127)55.1 ± 20.6257.2 ± 20.01
[EOS]Physical Functional Scale (n=125,127)70.2 ± 23.4972.5 ± 22.06
[EOS]Role Functional Scale (n=125,127)63.5 ± 32.4364.3 ± 29.68
[EOS]Emotional Functional Scale (n=124,127)74.4 ± 21.3677.3 ± 20.20
[EOS]Cognitive Functional Scale ( n=124,127)79.3 ± 24.9183.5 ± 19.30
[EOS]Social Functional Scale (n=124,127)73.3 ± 29.2872.6 ± 27.90
[EOS]Fatigue Symptom Scale (n=125,127)41.0 ± 26.4237.6 ± 23.80
[EOS]Nausea & Vomiting Scale (n=125,127)14.4 ± 23.7012.3 ± 20.70
[EOS]Pain Symptom Scale (n=125,127)30.4 ± 30.3121.1 ± 25.58
[EOS]Dyspnea Symptom Scale (n=124,127)31.5 ± 29.8534.1 ± 29.83
[EOS]Insomnia Symptom Scale( n=125,127)27.2 ± 26.5722.6 ± 28.45
[EOS]Appetite Loss Symptom Scale (n=125,127)26.9 ± 31.3126.0 ± 30.26
[EOS]Constipation Symptom Scale (n=125,127)17.6 ± 25.6012.1 ± 21.28
[EOS]Diarrhea Symptom Scale(n=124,127)9.7 ± 20.726.8 ± 15.34
[EOS]Financial Difficulties Scale (n=123,126)16.8 ± 27.4516.9 ± 27.24

Adverse events

Collected over Up to 21 months (throughout the study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
No Maintenance Treatment—70/128 (54.7%)105/128 (82%)
Maintenance Treatment Arm A—26/120 (21.7%)115/120 (95.8%)
Maintenance Treatment Arm B—42/125 (33.6%)120/125 (96%)
Most frequent serious events
Showing 10 of 111
Most frequent serious events
EventNo Maintenance TreatmentMaintenance Treatment Arm AMaintenance Treatment Arm B
Pulmonary embolismRespiratory, thoracic and mediastinal disorders9/1283/1202/125
PneumoniaInfections and infestations3/1281/1207/125
NeutropeniaBlood and lymphatic system disorders7/1280/1200/125
AnaemiaBlood and lymphatic system disorders4/1280/1201/125
Renal failureRenal and urinary disorders4/1280/1202/125
NauseaGastrointestinal disorders0/1282/1203/125
DyspnoeaRespiratory, thoracic and mediastinal disorders3/1281/1201/125
General physical health deteriorationGeneral disorders3/1281/1200/125
DehydrationMetabolism and nutrition disorders3/1280/1201/125
Decreased appetiteMetabolism and nutrition disorders3/1280/1200/125
Most frequent other events
Showing 10 of 52
Most frequent other events
EventNo Maintenance TreatmentMaintenance Treatment Arm AMaintenance Treatment Arm B
NauseaGastrointestinal disorders47/12873/12077/125
HypertensionVascular disorders23/12843/12055/125
AstheniaGeneral disorders25/12842/12031/125
FatigueGeneral disorders22/12822/12040/125
DiarrhoeaGastrointestinal disorders22/12816/12035/125
ConstipationGastrointestinal disorders21/12833/12032/125
VomitingGastrointestinal disorders21/12828/12033/125
Decreased appetiteMetabolism and nutrition disorders24/12823/12032/125
CoughRespiratory, thoracic and mediastinal disorders19/12827/12027/125
EpistaxisRespiratory, thoracic and mediastinal disorders17/12826/12024/125

Baseline characteristics

The Intent-to-treat (ITT) population included all the participants that were randomized.

Age, Continuous
Age, Continuous(years)Bevacizumab Maintenance Trt Arm ABevacizumab +Pemetrexed Maintenance Trt Arm BTotal
Mean59.5 ± 8.2559.3 ± 8.8659.4 ± 8.55
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab Maintenance Trt Arm ABevacizumab +Pemetrexed Maintenance Trt Arm BTotal
Female5554109
Male7074144
08

Study locations

91 sites
  • Beziers, 34500, France
  • Bordeaux, 33077, France
  • Bron, 69677, France
  • Caen, 14033, France
  • Caen, 14076, France
  • Clermont-ferrand, 63003, France
  • Creteil, 94010, France
  • GAP, 05007, France
  • Gleize, 69400, France
  • La Source, 45100, France
  • La Tronche, 38700, France
  • Lille, 59037, France
  • Limoges, 87039, France
  • Lyon, 69317, France
  • Marseille, 13915, France
  • Nancy, 54100, France
  • Nimes, 30900, France
  • Paris, 75571, France
  • Paris, 75674, France
  • Paris, 75970, France
  • Perpignan, 66046, France
  • Pierre Benite, 69495, France
  • Reims, 51092, France
  • Saint Priest En Jarez, 42770, France
  • Strasbourg, 67065, France
  • Toulon, 83041, France
  • Tours, 37044, France
  • Augsburg, 86150, Germany
  • Bad Berka, 99437, Germany
  • Berlin, 13125, Germany
  • Bonn, 53113, Germany
  • Ebensfeld, 96250, Germany
  • Frankfurt, 60488, Germany
  • Freiburg, 79106, Germany
  • Gauting, 82131, Germany
  • Grosshansdorf, 22927, Germany
  • Halle (Saale), 06120, Germany
  • Hamburg, 21075, Germany
  • Immenhausen, 34376, Germany
  • Karlsruhe, 76137, Germany
  • Leipzig, 04103, Germany
  • Minden, 32429, Germany
  • Muenchen, 80336, Germany
  • Oldenburg, 26121, Germany
  • Alexandroupolis, 68100, Greece
  • Napoli, Campania 80131, Italy
  • Aviano, Friuli-Venezia Giulia 33081, Italy
  • Roma, Lazio 00168, Italy
  • Novara, Piemonte 28100, Italy
  • Lecce, Puglia 73100, Italy
  • Sassari, Sardegna 07100, Italy
  • Pisa, Toscana 56124, Italy
  • Padova, Veneto 35128, Italy
  • Bundang City, 463-802, Korea, Republic of
  • Daegu, 700-712, Korea, Republic of
  • Gyeonggi-do, 410-769, Korea, Republic of
  • Seoul, 110746, Korea, Republic of
  • Seoul, 120-752, Korea, Republic of
  • Seoul, 135-710, Korea, Republic of
  • Seoul, 137-807, Korea, Republic of
  • Seoul, 138-736, Korea, Republic of
  • Amersfoort, 3818 ES, Netherlands
  • Amsterdam, 1066 CX, Netherlands
  • Breda, 4818 CK, Netherlands
  • Den Haag, 2504 LN, Netherlands
  • Eindhoven, 5623 EJ, Netherlands
  • Haarlem, 2035 RC, Netherlands
  • Hertogenbosch, 5211 RW, Netherlands
  • Nieuwegein, 3435 CM, Netherlands
  • Rotterdam, 3045 PM, Netherlands
  • Sittard-Geleen, 6162 BG, Netherlands
  • Zaandam, 1502 DV, Netherlands
  • Balashikha, 143900, Russian Federation
  • Irkutsk, 664035, Russian Federation
  • Krasnodar, 350086, Russian Federation
  • Moscow, 115478, Russian Federation
  • St Petersburg, 197089, Russian Federation
  • Palma de Mallorca, Islas Baleares 07198, Spain
  • Las Palmas de Gran Canaria, Las Palmas 35016, Spain
  • La Laguna, Tenerife 38320, Spain
  • Madrid, 28034, Spain
  • Madrid, 28041, Spain
  • Madrid, 28046, Spain
  • Gävle, 80187, Sweden
  • Linköping, 58185, Sweden
  • Lund, 22185, Sweden
  • Uppsala, 751 85, Sweden
  • Zürich, 8091, Switzerland
  • Antalya, 07070, Turkey
  • Izmir, 35110, Turkey
  • Al Ain, 15258, United Arab Emirates
09

References and documents

Publications

  • Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikstrom A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013 Aug 20;31(24):3004-11. doi: 10.1200/JCO.2012.42.3749. Epub 2013 Jul 8. PubMed 23835708 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2009
First posted
Aug 19, 2009
Start
Aug 2009
Primary completionActual
May 2011
CompletionActual
May 2011
Results first posted
Feb 22, 2016
Last update
Feb 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00961415
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 19, 2009
Start date
Aug 2009
Primary completion
May 2011
Completion
May 2011
Results posted
Feb 22, 2016
Last update
Feb 22, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cisplatin · Pemetrexed

Start the discussion